AzTrials
AzTrials

Reversible PulpitisPhase 1/2NCT07864181

TheraCal PT vs. Formocresol in Primary Molar Pulpotomies

A Phase 1/2 study testing Dual cured resin modified in people with Reversible Pulpitis, run by Hama University at 1 site in Syria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This prospective, randomized, parallel-group clinical trial evaluated the 12-month clinical and radiographic success rates of TheraCal PT versus formocresol in primary molar vital pulpotomies among 50 children aged 5 to 8 years. Read more about this study

Who is it for?
Ages 5 to 8 years
Conditions the study is for
Reversible Pulpitis
What is being tested?
Dual cured resin modified
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteSyria
Study dates
1 Jan 2024to 23 Dec 2025
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 8 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Pediatric patients aged between 5 and 8 years old.
  • Patients exhibiting "positive" or "definitely positive" behavior according to the Frankl Behavior Rating Scale to ensure complete clinical cooperation.
  • Children free from any systemic health conditions, congenital disorders, or chronic diseases that could contraindicate routine dental pulp therapy or alter biological healing mechanisms.
  • Target primary molars requiring vital pulpotomy with sufficient residual coronal tooth structure to support a definitive, leak-free stainless steel crown (SSC).
  • Primary molars presenting with mechanical or carious coronal pulp exposure during excavation, with no prior history of spontaneous or nocturnal pain.
  • Radicular pulp stumps exhibiting bright red hemorrhage upon surgical amputation that is easily controlled via light pressure with a sterile, saline-moistened cotton pellet within a maximum window of 3 to 5 minutes.
  • Preoperative periapical radiographs verifying intact root structures, with physiological root resorption, if present, restricted to less than the apical third of the total root length.
  • Preoperative radiographs demonstrating complete absence of pulpal or periodontal pathology, specifically characterized by the absence of periapical or furcation radiolucencies, the absence of pathological internal or external root resorption, and the maintenance of an intact periodontal ligament space and lamina dura.

Who cannot join

  • Pediatric patients demonstrating "negative" or "definitely negative" behavior on the Frankl Behavior Rating Scale, which would compromise the quality of the clinical intervention.
  • Children with compromised systemic health, congenital disorders, or medical conditions that contraindicate routine dental pulp therapy or interfere with normal systemic healing.
  • Target primary teeth presenting with any pre-existing clinical pathology, including abnormal tooth mobility, sensitivity to vertical or horizontal percussion, localized soft tissue swelling, or fistulous/sinus tracts.
  • Presence of purulent exudate or suppuration discharging from the gingival sulcus or pulp chamber.
  • History of spontaneous, nocturnal, or persistent pain indicative of irreversible pulpitis.
  • Radicular pulp stumps demonstrating dark, profuse, or uncontrollable hemorrhage upon surgical amputation, highly suggestive of extensive radicular inflammation or partial tissue necrosis.
Show all 9Show fewer
  • Preoperative radiographic evidence of pulpal or periradicular pathosis, explicitly characterized by periapical radiolucency, inter-radicular furcation radiolucency, or loss of an intact periodontal ligament space and lamina dura.
  • Radiographic evidence of pathological internal or external root resorption. Primary teeth with advanced physiological root resorption extending beyond the apical third of the total root length.
  • Primary molars with extensive coronal destruction that renders the tooth non-restorable or unable to support a definitive preformed stainless steel crown (SSC).

Trial locations and contacts

1 site in 1 country.

Syria1 site
  • Hama University

    Hama

Other trials in Syria

About this study

Official title: TheraCal PT Versus Formocresol in Primary Molar Pulpotomies: Clinical and Radiographic Outcomes at 12 Months Follow-Up

This prospective, randomized, parallel-group clinical trial evaluated the 12-month clinical and radiographic success rates of TheraCal PT versus formocresol in primary molar vital pulpotomies among 50 children aged 5 to 8 years. At the conclusion of the follow-up period, both materials demonstrated a 100% clinical success rate, while radiographic success rates were 92% for the formocresol group and 80% for the TheraCal PT group, showing no statistically significant differences between the two treatments.

Read the detailed description

Vital pulpotomy is a standard therapeutic intervention in pediatric dentistry aimed at preserving primary molars with carious or mechanical pulp exposure, thereby maintaining tooth function until physiological exfoliation. Traditionally, Formocresol has served as the conventional benchmark medicament; however, concerns regarding its potential systemic toxicity and tissue fixation have prompted the continuous investigation of safer, bioactive alternatives. TheraCal PT is a novel, dual-cured, resin-modified calcium silicate-based material designed to stimulate rapid dentin bridge formation through sustained calcium ion release and alkaline pH maintenance. This randomized controlled trial was established to evaluate and compare the long-term clinical and radiographic efficacy of TheraCal PT against conventional Formocresol in vital primary teeth pulpotomies over a 12-month investigative window.

Study Settings and Population:

This prospective, parallel-group, randomized clinical investigation was conducted at the Postgraduate Clinics of the Department of Pediatric Dentistry, Faculty of Dentistry at Hama University, Syria. The trial protocol was reviewed and formally approved by the Institutional Review Board and the Research Ethics Committee of Hama University. The study population comprised 50 primary molars requiring vital pulp therapy in cooperative pediatric patients aged 5 to 8 years (one molar per child). Legally authorized guardians of all eligible children received a comprehensive presentation regarding the specific trial objectives, risks, and benefits prior to signing a definitive, written informed consent document in compliance with the Declaration of Helsinki.

Eligibility and Screening Criteria:

Strict clinical and radiographic selection criteria were implemented to guarantee sample homogeneity. Eligible pediatric participants were required to exhibit cooperative "positive" or "definitely positive" behavior according to the Frankl Behavior Rating Scale. All participants were systemically healthy, presenting with no conditions that could alter healing mechanisms. Clinically, each target primary molar possessed a restorable coronal tooth architecture. The protocol targeted vital teeth presenting with mechanical or carious pulpal exposure during excavation, with an absolute absence of prior spontaneous or nocturnal pain. Upon controlled surgical excision of the coronal pulp tissue, radicular pulp stumps were required to demonstrate bright red hemorrhage easily controlled via light pressure with a sterile, saline-moistened cotton pellet within 3 to 5 minutes.

Radiographically, all included primary molars exhibited stable root structures with physiological root resorption limited to less than the apical third of the total root length, verified by preoperative periapical radiographs. Target teeth were entirely free from pre-existing radiographic pathosis, explicitly defined by the absence of periapical or inter-radicular furcation radiolucencies, the total absence of pathological internal or external root resorption, and the maintenance of an intact periodontal ligament space. Children exhibiting uncooperative behaviors, or teeth presenting with localized swelling, mobility, fistulous tracts, tenderness to percussion, or uncontrollable radicular hemorrhage were systematically excluded.

Randomization and Allocation Concealment:

The 50 primary teeth were randomly allocated in a strict 1:1 ratio into either the Experimental Group (TheraCal PT) or the Active Control Group (Formocresol), yielding 25 test sites per cohort. The random allocation sequence was computer-generated prior to clinical initiation via an online randomization software package. To prevent selection bias, sequentially numbered, opaque, sealed envelopes (SNOSE) containing the treatment assignments were prepared and maintained by an independent co-investigator. The envelope was exclusively opened by the operational clinician immediately preceding the active pulp management phase, after local anesthesia was established and rubber dam isolation was secured.

Standardized Operative Intervention:

All procedures were executed under rigorous aseptic conditions by a single operator. Local anesthesia was established utilizing 2% lidocaine with 1:100,000 epinephrine, followed by rubber dam application. Access cavity preparation and complete excavation of deep carious dentin were performed. Upon unroofing the pulp chamber, the coronal pulp tissue was amputated at the canal orifices. Local hemostasis was initiated using a sterile cotton pellet moistened with normal saline for up to 5 minutes. Following successful control of hemorrhage, the allocated intervention was performed:

  • Formocresol Group: A sterile cotton pellet lightly dampened with a 1:5 dilution of Buckley's Formocresol solution was applied to the radicular pulp stumps for 5 minutes. A sub-base layer of zinc oxide eugenol (ZOE) cement was then placed over the pulp floor.
  • TheraCal PT Group: TheraCal PT cement was directly adapted over the radicular pulp stumps and the entire pulpal floor at a uniform thickness of approximately 2 mm. Photo-polymerization was executed using a calibrated LED curing light for a continuous duration of 10 seconds at a stable output of 1100 mW/cm².

Immediately following sub-base applications, all treated primary molars across both cohorts were definitively restored with preformed stainless steel crowns (SSCs) according to the guidelines of the American Academy of Pediatric Dentistry (AAPD).

Success Evaluation and Follow-up Protocol:

Treated subjects were systematically recalled for blinded clinical and radiographic examinations at standardized intervals up to the definitive 12-month endpoint. Clinical success was quantified by the absolute absence of subjective or objective signs or symptoms of pathology (pain, swelling, marginal erythema, fistulous tracts, abnormal mobility, or tenderness to percussion). Radiographic success was evaluated using standardized periapical radiographs achieved via the parallel technique, defined as the total absence of new periapical radiolucencies, inter-radicular furcation radiolucencies, or pathological internal/external root resorption.

Being tested
Dual cured resin modified
Keywords
Pulpotomy, Tooth, Deciduous, Dental Pulp Exposure, Dental Caries
Medical subject headings
Dental Pulp Exposure, Dental Caries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dual cured resin modifiedDrug

    Total absence of pulpal and periradicular radiographic pathology, explicitly evaluated via standardized periapical radiographs using the paralleling technique. Success is characterized by the absence of new or progressive periapical radiolucency, inter-radicular furcation radiolucency, or pathological internal or external root resorption. The appearance of any single radiographic lesion is defined as radiographic failure.

Study groups in NCT07864181
Study groupRoleWhat they receive
Clinical Success RateExperimentalTotal absence of subjective or objective clinical signs and symptoms of pulpal or periodontal pathology. This includes the absolute absence of spontaneous or nocturnal pain, tenderness to percussion, localized swelling, fistulous/sinus tracts, or abnormal physiological tooth mobility. The presence of any single clinical sign or symptom is defined as clinical failure.
Receives: Drug: Dual cured resin modified
Radiographic Success RateExperimentalTotal absence of pulpal and periradicular radiographic pathology, explicitly evaluated via standardized periapical radiographs using the paralleling technique. Success is characterized by the absence of new or progressive periapical radiolucency, inter-radicular furcation radiolucency, or pathological internal or external root resorption. The appearance of any single radiographic lesion is defined as radiographic failure.
Receives: Drug: Dual cured resin modified

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Primary Molars Demonstrating Clinical Success

    Total absence of subjective or objective clinical signs and symptoms of pulpal or periodontal pathology. This includes the absolute absence of spontaneous or nocturnal pain, tenderness to percussion, localized swelling, fistulous/sinus tracts, or abnormal physiological tooth mobility. The presence of any single clinical sign or symptom is defined as clinical failure.

    Measured: 12 months

Secondary outcomes (1)
  1. Percentage of Primary Molars Demonstrating Radiographic Success

    Total absence of pulpal and periradicular radiographic pathology, explicitly evaluated via standardized periapical radiographs using the paralleling technique. Success is characterized by the absence of new or progressive periapical radiolucency, inter-radicular furcation radiolucency, or pathological internal or external root resorption. The appearance of any single radiographic lesion is defined as radiographic failure.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Oct 2026
  2. Study start1 Jan 2024
  3. Primary completion3 Jun 2025
  4. Study completion23 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07864181
Sponsor's protocol ID
Hama University-Pediatric
Status last verified
Oct 2026
First submitted
27 Sep 2026
Last updated
7 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Sahin N, Saygili S, Akcay M. Clinical, radiographic, and histological evaluation of three different pulp-capping materials in indirect pulp treatment of primary teeth: a randomized clinical trial. Clin Oral Investig. 2021 Jun;25(6):3945-3955. doi: 10.1007/s00784-020-03724-4. Epub 2021 Jan 6.

    PubMed 33404764
  • Amrollahi N, Karimi R, Shariati F. Clinical and radiographic success of TheraCal versus Formocresol in primary teeth pulpotomy: A systematic review and meta-analysis. Saudi Dent J. 2024 Aug;36(8):1058-1065. doi: 10.1016/j.sdentj.2024.06.008. Epub 2024 Jun 6.

    PubMed 39176161
  • Baranwal HC, Mittal N, Samad S, Ayubi A, Aggarwal H, Kharat SM. Comparative evaluation of dual-cure resin (TheraCal PT) and Biodentine in coronal pulpotomy of patients with symptoms indicative of irreversible pulpitis: A randomized clinical trial. J Conserv Dent Endod. 2024 Aug;27(8):822-827. doi: 10.4103/JCDE.JCDE_280_24. Epub 2024 Aug 7.

    PubMed 39372577
  • Bakhtiar H, Nekoofar MH, Aminishakib P, Abedi F, Naghi Moosavi F, Esnaashari E, Azizi A, Esmailian S, Ellini MR, Mesgarzadeh V, Sezavar M, About I. Human Pulp Responses to Partial Pulpotomy Treatment with TheraCal as Compared with Biodentine and ProRoot MTA: A Clinical Trial. J Endod. 2017 Nov;43(11):1786-1791. doi: 10.1016/j.joen.2017.06.025. Epub 2017 Aug 16.

    PubMed 28822566
  • Hassanpour S, Aminabadi NA, Rahbar M, Erfanparast L. Comparison between the Radiographic and Clinical Rates of Success for TheraCal and MTA in Primary Tooth Pulpotomy within a 12-Month Follow-Up: A Split-Mouth Clinical Trial. Biomed Res Int. 2023 Apr 19;2023:8735145. doi: 10.1155/2023/8735145. eCollection 2023.

    PubMed 37124935

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Dual cured resin modified in people with Reversible Pulpitis, run by Hama University at 1 site in Syria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Primary Molars Demonstrating Clinical Success (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07864181, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in